rethinkPeptides Search
Menu
Home / Research library
Study breakdown

BPC-157 Heals NSAID Gut Damage AND Reduces Arthritis at the Same Time

RPEP-004281997Sikiric, P; Seiwerth, S; Grabarevic, Z; Rucman, R; Petek, M; Jagic, V; Turkovic, B; Rotkvic, I; Mise, S; Zoricic, I; Konjevoda, P; Perovic, D; Simicevic, V; Separovic, J; Hanzevacki, M; Ljubanovic, D; Artukovic, B; Bratulic, M; Tisljar, M; Rekic, B; Gjurasin, M; Miklic, P; Buljat, G
Animal StudyPreliminary evidence
The takeaway

BPC-157 simultaneously protected against NSAID-induced gut damage and improved chronic adjuvant arthritis in rats, showing dual gastroprotective and anti-inflammatory/analgesic effects.

Protects gut + fights arthritis

BPC-157 simultaneously shielded against NSAID stomach damage and improved chronic adjuvant arthritis

What the researchers found

BPC-157 both protected against NSAID-induced GI lesions and improved chronic adjuvant arthritis, demonstrating simultaneous gastroprotective and anti-inflammatory effects.

Why it matters

NSAIDs are the most common treatment for arthritis but cause serious gut damage. A peptide that protects the gut while also reducing inflammation could solve a major clinical dilemma.

How the study worked

Rat model of adjuvant arthritis with concurrent NSAID administration. BPC-157 was tested for both gastroprotective effects (against NSAID damage) and arthritis improvement.

What this study cannot tell us

Animal study; adjuvant arthritis may not fully model human rheumatoid arthritis. Specific doses, timing, and quantitative improvements not detailed.

How to read the evidence

Moderate animal evidence demonstrating dual therapeutic effects in a clinically relevant model.

When this study was published

Published in 1997, this is frequently cited as evidence for BPC-157's anti-inflammatory properties beyond gut healing.

The bigger picture

This study positioned BPC-157 as a potential co-therapy with NSAIDs — protecting against their gut side effects while adding its own anti-inflammatory benefit.

Questions still open

  • Could BPC-157 be co-administered with NSAIDs to prevent gastropathy while enhancing anti-inflammatory effects?
  • Does BPC-157 work through the same anti-inflammatory pathways as NSAIDs?

Common questions

Why is this finding important for NSAID users?
NSAIDs like ibuprofen and naproxen cause stomach ulcers in many users. BPC-157 could potentially protect the stomach while the NSAID treats inflammation — addressing both sides of a common clinical problem.
Does BPC-157 replace NSAIDs?
Not necessarily. This study shows BPC-157 has its own anti-inflammatory and pain-relieving properties alongside gastroprotection. It might complement NSAIDs or potentially allow lower NSAID doses.

Read the original research

Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats.

Journal of physiology, Paris, 91(3-5), 113-22

View on PubMed ↗

Citation

Sikiric, P; Seiwerth, S; Grabarevic, Z; Rucman, R; Petek, M; Jagic, V; Turkovic, B; Rotkvic, I; Mise, S; Zoricic, I; Konjevoda, P; Perovic, D; Simicevic, V; Separovic, J; Hanzevacki, M; Ljubanovic, D; Artukovic, B; Bratulic, M; Tisljar, M; Rekic, B; Gjurasin, M; Miklic, P; Buljat, G. (1997). Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats.. Journal of physiology, Paris, 91(3-5), 113-22.